Discontinued — last reported Q1 '23
Thermo Fisher Scientific Restricted Cash decreased by 8.3% to $22.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 46.7%, from $15.00M to $22.00M. Over 4 years (FY 2020 to FY 2024), Restricted Cash shows an upward trend with a 77.8% CAGR.
An increase may signal new regulatory requirements or specific contractual obligations, while a decrease indicates the release of previously tied-up capital.
Cash balances that are legally or contractually restricted from being used for general corporate purposes. This often in...
Common in payment processors due to regulatory compliance and settlement-related escrow requirements.
restricted_cash| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.00M | $1.00M | $1.00M | $1.00M | $1.00M | $1.00M | $1.00M | $7.00M | $7.00M | $7.00M | $14.00M | $14.00M | $14.00M | $15.00M | $10.00M | $22.00M | $24.00M | $22.00M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +600.0% | +0.0% | +0.0% | +100.0% | +0.0% | +0.0% | +7.1% | -33.3% | +120.0% | +9.1% | -8.3% |
| YoY Change | — | — | — | — | +0.0% | +0.0% | +0.0% | +600.0% | +600.0% | +600.0% | >999% | +100.0% | +100.0% | +114.3% | -28.6% | +57.1% | +71.4% | +46.7% |
We use cookies for analytics. See our Privacy and Cookie Policy.